Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not ...

Novo Nordisk initiated study validates the power of proteomics to provide unique insights into mechanisms of action and ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

Weight management platform Found is today launching oral semaglutide dissolvable tablets for individuals looking for ...

Biomea Fusion (BMEA) announce compelling results from in vivo studies of icovamenib in combination with semaglutide. Highlights of the Study: ...

A new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...

This is the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and ...

Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...